World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
89
Citations
44830
World Ranking
12441
National Ranking
6371

David H. Vesole publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where David H. Vesole sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 494 publications — 57th percentile

57% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

David H. Vesole D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where David H. Vesole sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 89 D-Index — 38th percentile

38% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

David H. Vesole is affiliated with Rutgers, The State University of New Jersey in the United States. Their research primarily focuses on the field of medicine, with significant contributions to hematology, molecular biology, oncology, genetics, and pathology and forensic medicine.

The scientist's work covers a broad array of topics, emphasizing multiple myeloma research and treatments, protein degradation and inhibitors, chronic lymphocytic leukemia research, CAR-T cell therapy research, peptidase inhibition and analysis, chronic myeloid leukemia treatments, and hematopoietic stem cell transplantation.

David H. Vesole has published extensively in various scientific journals. Their frequent publication venues include the following:

  • Blood
  • Journal of Clinical Oncology
  • Clinical Lymphoma Myeloma & Leukemia
  • Cancer
  • Transplantation and Cellular Therapy

Several recent publications illustrate the areas of their research interest and collaboration, including:

  • Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM). (2020, Journal of Clinical Oncology)
  • Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. (2020, Cancer)
  • KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer. (2020, Kidney International)
  • Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. (2020, Leukemia)
  • Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT). (2022, Blood Cancer Journal)

Collaboration with frequent co-authors appears to be a significant element of their research activity. Frequent co-authors include:

  • Noa Biran
  • David S. Siegel
  • Harsh Parmar
  • Parameswaran Hari
  • Pooja Phull

Best Publications

  • International uniform response criteria for multiple myeloma

    B. G. M. Durie;J.-L. Harousseau;J. S. Miguel;J. Blade

  • Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

    Robert A. Kyle;J. Anthony Child;Kenneth Anderson;Bart Barlogie

  • Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.

    Joan BladÉ;Diana Samson;Donna Reece;Jane Apperley

  • Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease

    Andrew J Ullmann;Jeffrey H Lipton;David H Vesole;Pranatharthi Chandrasekar

  • Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

    S Vincent Rajkumar;Susanna Jacobus;Natalie S Callander;Rafael Fonseca

  • Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group

    S. Vincent Rajkumar;Emily Blood;David Vesole;Rafael Fonseca

  • Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

    Paul G. Richardson;Edie Weller;Sagar Lonial;Andrzej J. Jakubowiak

  • Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

    A. Palumbo;S. V. Rajkumar;M. A. Dimopoulos;P. G. Richardson

  • Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

    R A Kyle;B G M Durie;S V Rajkumar;O Landgren

  • Micafungin versus Fluconazole for Prophylaxis against Invasive Fungal Infections during Neutropenia in Patients Undergoing Hematopoietic Stem Cell Transplantation

    Jo Anne H. Van Burik;Voravit Ratanatharathorn;Daniel E. Stepan;Carole B. Miller

  • Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.

    Bart Barlogie;Sundar Jagannath;David H. Vesole;Sally Naucke

  • Graft-versus-myeloma effect: proof of principle

    Guido Tricot;David H. Vesole;Sundar Jagannath;Jennifer Hilton

  • Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma

    B. Barlogie;S. Jagannath;K.R. Desikan;S. Mattox

  • The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone.

    Neal Flomenberg;Steven M. Devine;John F. DiPersio;Jane L. Liesveld

  • Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients

    Guido Tricot;Sundar Jagannath;David Vesole;Jean Nelson

  • Rapid Mobilization of CD34+ Cells Following Administration of the CXCR4 Antagonist AMD3100 to Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma

    Steven M. Devine;Neal Flomenberg;David H. Vesole;Jane Liesveld

  • Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities

    Guido Tricot;Bart Barlogie;Sundar Jagannath;Dwayne Bracy

  • Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody.

    Joseph T. Beck;Su-Ming Hsu;John Wijdenes;Regis Bataille

  • Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications.

    Radek Spisek;Anna Charalambous;Amitabha Mazumder;David H. Vesole

  • International Myeloma Workshop Consensus Panel 1. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

    Sv Rajkumar;Jl Harousseau;B Durie;Kc Anderson

Frequent Co-Authors

David S. Siegel
David S. Siegel Hackensack University Medical Center
Parameswaran Hari
Parameswaran Hari Medical College of Wisconsin
Sundar Jagannath
Sundar Jagannath Icahn School of Medicine at Mount Sinai
Sagar Lonial
Sagar Lonial Emory University
Paul G. Richardson
Paul G. Richardson Harvard University
Guido Tricot
Guido Tricot University of Iowa
Ravi Vij
Ravi Vij Washington University in St. Louis
Sergio Giralt
Sergio Giralt Memorial Sloan Kettering Cancer Center
Hillard M. Lazarus
Hillard M. Lazarus Case Western Reserve University
Nikhil C. Munshi
Nikhil C. Munshi Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in the healthcare field but want to explore alternative pathways or enhance your credentials, online degrees offer flexible and affordable options. Programs like the cheapest online mha programs are ideal for those aiming for leadership or administrative positions within hospitals, clinics, or public health organizations.

Nursing professionals seeking advanced clinical roles might consider the cheapest dnp online programs, which prepare graduates for top practice and leadership jobs. Pharmacists and pharmacy technicians can further their expertise with online pharm d programs, opening doors to research, teaching, or specialized practice.

For those interested in the digital side of healthcare, a him bachelor's degree online can lead to in-demand roles managing patient data, health IT systems, and regulatory compliance. Exploring these online degrees can expand your career options, improve your earning potential, and allow you to make a significant impact in the evolving healthcare landscape.

Best Scientists Citing David H. Vesole

Trending Scientists

Recently Published Articles